Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
14 mars 2019 16h27 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
13 mars 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02 janv. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
20 nov. 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13 nov. 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
26 sept. 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
30 août 2018 16h07 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
21 juin 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
18 juin 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
13 mars 2018 14h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...